Skip to main content

Table 2 Univariate analyses of biomarkers for progressive disease as best clinical benefit in bmCRPC on Abiraterone-therapy

From: Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

Variable OR (95 % CI) p
PSA decline ≥ 50 % no vs. yes 24.9 (3.1–202.1) 0.003
No-Bouncing vs. ALP-Bouncing 11.6 (1.4–93.5) 0.021
ALP rising after 12 w yes vs. no 6.3 (1.7–22.8) 0.006
Visceral Mets. yes vs. no 4.0 (1.2–13.9) 0.028
ECOG 2 vs. 0–1 3.3 (1.0–11.1) 0.055
LDH normalization no vs. yes 3.0 (0.6–15.6) 0.192
LDH BL > UNL yes vs. no 2.2 (0.4–10.9) 0.338
ALP BL > UNL yes vs. no 1.3 (0.4–4.3) 0.698
AA post-CTX vs. pre-CTX 1.2 (0.4–3.7) 0.769
Lnn. Mets. yes vs. no 1.2 (0.4–3.8) 0.769
GS ≥ 8 vs. GS < 8 1.2 (0.3–4.4) 0.835